Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. A
A logo

A Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
127.560
Open
125.560
VWAP
126.60
Vol
4.33M
Mkt Cap
35.89B
Low
125.165
Amount
548.71M
EV/EBITDA(TTM)
19.86
Total Shares
282.43M
EV
37.43B
EV/OCF(TTM)
25.78
P/S(TTM)
4.99
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
Show More

Events Timeline

(ET)
2026-06-03
07:10:00
Agilent Technologies Partners with OpenAI and BCG to Accelerate AI Deployment
select
2026-06-02 (ET)
2026-06-02
16:30:00
Agilent Technologies Receives FDA Approval for Expanded PD-L1 Testing Indications
select
2026-05-28 (ET)
2026-05-28
16:20:00
Major U.S. Averages Advance as Investors Weigh AI Enthusiasm Against Fiscal Outlook
select
2026-05-28
12:00:00
Major Averages Rise at Noon as Investors Weigh AI Enthusiasm and Fiscal Outlook
select

News

PRnewswire
2.0
06-15PRnewswire
Honeywell Board Approves Aerospace Spin-Off
  • Spin-Off Approval: Honeywell's Board of Directors has formally approved the spin-off of its Aerospace division, expected to be completed on June 29, 2026, marking a significant milestone in the company's portfolio transformation over the past three years aimed at enhancing the competitiveness of both independent entities.
  • Stock Distribution Details: On June 29, 2026, Honeywell will distribute shares of Aerospace common stock to shareholders on a pro-rata basis, with one share of Aerospace stock for every two shares of Honeywell common stock held, thereby enhancing shareholder returns.
  • Exchange Listing Arrangements: Aerospace common stock is expected to begin trading on Nasdaq on a
PRnewswire
8.5
06-05PRnewswire
Honeywell Announces Aerospace Spin-Off Plan
  • Spin-Off Date Set: Honeywell's Board of Directors has established June 15, 2026, as the record date for the spin-off of its Aerospace business, with a distribution expected on June 29, 2026, at a ratio of one share of Aerospace stock for every two shares of Honeywell common stock, marking a significant restructuring step for the company.
  • Independent Trading Launch: Aerospace common stock is set to begin trading on Nasdaq under the ticker symbol 'HONA' on June 29, 2026, providing Honeywell Aerospace with an independent capital market platform that enhances its competitive position in the aerospace sector.
  • Reverse Stock Split: Honeywell also announced a 1-for-2 reverse stock split, expected to reduce the outstanding shares from approximately 634 million to about 317 million, aimed at improving earnings per share and optimizing capital structure to boost investor confidence.
  • Tax Implications Clarified: The spin-off is expected to be tax-free for Honeywell shareholders for U.S. federal income tax purposes, except for cash received for fractional shares, which will help attract more investors to focus on the company's long-term value creation potential.
seekingalpha
9.0
06-03seekingalpha
FDA Expands Agilent's PD-L1 Test Indication for Keytruda Use
  • Indication Expansion: The FDA has expanded the indication for Agilent's PD-L1 IHC 22C3 pharmDx test to include four new tumor types, such as esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastroesophageal junction adenocarcinoma, enhancing the test's value in cancer treatment decision-making.
  • Market Impact: This expansion allows the PD-L1 IHC 22C3 pharmDx test to assist more patients in accessing Merck's Keytruda (pembrolizumab) treatment, which is expected to boost Agilent's competitiveness in the cancer diagnostics market, particularly in the rapidly growing immunotherapy sector.
  • Technical Platform: The test is performed on the Dako Omnis platform, integrating advanced detection technology that ensures accuracy and reliability of results, thereby enhancing physician confidence in treatment choices.
  • Future Outlook: With the FDA's approval, Agilent is poised to capture a larger market share in the future, potentially attracting more investor interest in its innovative capabilities and market potential within the biotechnology sector.
Newsfilter
7.5
06-03Newsfilter
Agilent Partners with OpenAI and BCG to Accelerate AI Deployment
  • Strategic Collaboration: Agilent has partnered with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence across its products, operations, and customer workflows, reflecting the company's ambition and commitment to execution in the AI domain.
  • Innovation Drive: By integrating advanced AI capabilities, Agilent aims to enhance the intelligence of its products and services, with plans to significantly improve customer experience and accelerate its new product pipeline over the next six to twelve months.
  • Competitive Advantage: This collaboration will enable Agilent to transform AI into a competitive advantage, shifting from pilot projects to scaled deployment, thereby redefining how value is created across the enterprise and enhancing decision-making support.
  • Resource Integration: By combining Agilent's scientific expertise with OpenAI's AI research and BCG's large-scale transformation experience, the partnership aims to identify, build, and scale high-impact applied AI solutions, enhancing the overall innovation capacity of the enterprise.
Newsfilter
8.5
06-02Newsfilter
Agilent Receives FDA Approval for Expanded PD-L1 Testing
  • Platform Expansion: Agilent announced FDA approval for the expanded use of PD-L1 IHC 22C3 pharmDx on the Dako Omnis platform, facilitating testing for patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric adenocarcinoma, thereby increasing access to KEYTRUDA® treatment for more patients.
  • Workflow Optimization: This approval allows pathology laboratories to consolidate PD-L1 testing across multiple tumor types within a single Dako Omnis workflow, significantly enhancing automation and operational efficiency, which meets the laboratories' demand for standardized testing.
  • Multi-Site Study Validation: Agilent conducted a multisite external platform performance comparison study that validated the concordance of PD-L1 IHC 22C3 pharmDx results across different staining platforms, ensuring reliability at appropriate CPS cutoffs, thus boosting confidence in clinical applications.
  • Strategic Market Alignment: This expansion aligns with Agilent's strategic goals in the clinical diagnostics field, aiming to provide more convenient testing services that support clinicians in effectively identifying patients eligible for immunotherapy, further solidifying its leadership position in the biomarker testing market.
seekingalpha
6.5
06-02seekingalpha
Valuation Analysis of U.S. Healthcare Stocks
  • High Valuation Companies: Among U.S. healthcare stocks with market caps over $10 billion, Agilent Technologies (A) stands out with a valuation grade of F, indicating its high valuation relative to peers, which may influence investor purchasing decisions.
  • Valuation Scoring Mechanism: Seeking Alpha's valuation grades assess stocks based on a comprehensive set of metrics including P/E, PEG, and EV/Sales, providing crucial insights for investors regarding relative pricing within the sector.
  • Other High Valuation Stocks: Companies like Danaher Corporation (DHR) and GE HealthCare Technologies (GEHC) also received an F valuation grade, highlighting the high valuation risks these firms face in the current market environment, prompting investors to reassess their portfolios.
  • Market Dynamics: Despite Summit Therapeutics (SMMT) facing downward pressure following recent clinical data releases, the overall valuation landscape for healthcare stocks indicates a cautious investor sentiment towards high valuation stocks, potentially affecting future capital flows.
Wall Street analysts forecast A stock price to rise
13 Analyst Rating
Wall Street analysts forecast A stock price to rise
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
160.00
Averages
171.67
High
180.00
Current: 0.000
sliders
Low
160.00
Averages
171.67
High
180.00
Piper Sandler
David Westenberg
Neutral
initiated
$150
AI Analysis
2026-06-11
Reason
Piper Sandler
David Westenberg
Price Target
$150
AI Analysis
2026-06-11
initiated
Neutral
Reason
Piper Sandler analyst David Westenberg initiated coverage of Agilent with a Neutral rating and $150 price target. The firm launched coverage of the life science tools sector with a \"feet in the shallow end of the pool\" approach. Piper only recommends buying Twist Bioscience for its growing exposure to next generation drug discovery and development. Headwinds for the group faces from biotech and academic spending as well as China exposure will likely improve near term, the analyst tells investors in a research note. However, Piper wants to see some of the next big growth drivers materialize before recommending more of the stocks. Investors \"can buy multi-year growth compounding stocks early, middle, and late into their growth cycles but would simply prefer to wait out a couple quarters for the sector to perform like it did pre-Covid,\" the firm contends.
HSBC
Sidharth Sahoo
Buy
to
Buy
downgrade
$180 -> $165
2026-06-03
Reason
HSBC
Sidharth Sahoo
Price Target
$180 -> $165
2026-06-03
downgrade
Buy
to
Buy
Reason
HSBC analyst Sidharth Sahoo lowered the firm's price target on Agilent to $165 from $180 and keeps a Buy rating on the shares. The firm says market expectations on life science tools "remain bearish" with allocation tilted towards managed care and therapeutics within healthcare. While the tools sector is priced for disappointment, HSBC sees "green shoots of recovery," notably in bioprocessing and quality assurance, the analyst tells investors in a research note. The firm adjusted target prices to reflect risk-adjusted return expectations. HSBC's preferred ideas are Waters, Iqvia, and Sartorius.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for A
Unlock Now

Valuation Metrics

The current forward P/E ratio for Agilent Technologies Inc (A.N) is 20.53, compared to its 5-year average forward P/E of 24.85. For a more detailed relative valuation and DCF analysis to assess Agilent Technologies Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
24.85
Current PE
20.53
Overvalued PE
28.89
Undervalued PE
20.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
20.22
Current EV/EBITDA
17.42
Overvalued EV/EBITDA
23.26
Undervalued EV/EBITDA
17.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
5.66
Current PS
4.55
Overvalued PS
6.49
Undervalued PS
4.82

Financials

AI Analysis
Annual
Quarterly

Whales Holding A

W
Walleye Capital LLC
Holding
A
+31.66%
3M Return
R
RobecoSAM AG
Holding
A
+26.64%
3M Return
A
Argenta Asset Management SA
Holding
A
+20.89%
3M Return
L
Logan Capital Management, Inc.
Holding
A
+19.22%
3M Return
P
Pictet Asset Management Limited
Holding
A
+18.36%
3M Return
C
Candriam, Société En Commandite Par Actions
Holding
A
+17.03%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Agilent Technologies Inc (A) stock price today?

The current price of A is 127.06 USD — it has increased 2.2

What is Agilent Technologies Inc (A)'s business?

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.

What is the price predicton of A Stock?

Wall Street analysts forecast A stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for A is171.67 USD with a low forecast of 160.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Agilent Technologies Inc (A)'s revenue for the last quarter?

Agilent Technologies Inc revenue for the last quarter amounts to 1.83B USD, increased 10.01

What is Agilent Technologies Inc (A)'s earnings per share (EPS) for the last quarter?

Agilent Technologies Inc. EPS for the last quarter amounts to 1.20 USD, increased 60.00

How many employees does Agilent Technologies Inc (A). have?

Agilent Technologies Inc (A) has 18100 emplpoyees as of June 21 2026.

What is Agilent Technologies Inc (A) market cap?

Today A has the market capitalization of 35.89B USD.